CIRSE Registry for SIR-Spheres in France (CIRT-FR) (CIRT-FR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03256994|
Recruitment Status : Recruiting
First Posted : August 22, 2017
Last Update Posted : January 31, 2019
|Condition or disease||Intervention/treatment|
|Liver Cancer||Device: Yttrium-90 loaded SIR-Spheres microspheres Behavioral: QLQ-C30 with HCC module|
Selective internal radiation therapy (SIRT), also called radioembolisation (RE), with SIR-Spheres microspheres is an endovascular procedure, included within the interventional oncologic technologies to treat primary and secondary liver tumours. Using a microcatheter, a precise dose of resin microspheres is released in the hepatic artery, where they are carried into the arterioles and selectively lodge in the tumour microvasculature. The microspheres are loaded with the radioactive yttrium-90, a high-energy beta-emitting isotope with a half-life of 64.1 hours. Following administration, 94% of the radiation is delivered in 11 days.
In France, SIR-Spheres are listed as reimbursable by the national health authorities (Haute Autorité de Santé [HAS]). In order to evaluate the reimbursement after five years, all patients treated with SIR-Spheres will be entered into a registry that collects data on the real-life clinical application of SIRT and reports to the national authorities.
The goal of the research project is to gain a better understanding of the real-life clinical application of radioembolisation with SIR-Spheres and the impact of the treatment in clinical practice. Secondary objectives will include, safety in terms of adverse events; effectiveness based on overall survival, progression free survival (PFS), hepatic free survival (liver specific PFS); SIRT in relation to surgery and ablation (before and after SIRT treatment) and quality of life.
To better understand the palliative aspect of the treatment, acquisition of the change in quality of life is included by means of EORTC's validated quality of life questionnaire QLQ C30 with accompanying HCC module to measure quality of life in patients with hepatocellular carcinoma.
Besides data collection on the initial treatment, it will be advised to collect follow-up data and quality of life data every three months for a minimum of 24 months after treatment.
CIRT-FR is a post-market, prospective, non-randomized, observational study. Patients are only asked to be enrolled when they are treated with SIR-Spheres microspheres as part of their treatment determined by the treating clinician. In no way will participation of the patient in the registry impact their treatment plan, or influence the quality of the treatment.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||200 participants|
|Target Follow-Up Duration:||24 Months|
|Official Title:||CIRSE Registry for SIR-Spheres in France (CIRT-FR)|
|Actual Study Start Date :||August 1, 2017|
|Estimated Primary Completion Date :||May 1, 2021|
|Estimated Study Completion Date :||February 1, 2022|
- Device: Yttrium-90 loaded SIR-Spheres microspheres
Selective internal radiation therapy (SIRT), also called radioembolisation (RE), with SIR-Spheres microspheres is an endovascular procedure, included within the interventional oncologic technologies to treat primary and secondary liver tumours. Using a microcatheter, a precise dose of resin microspheres is released in the hepatic artery, where they are carried into the arterioles and selectively lodge in the tumour microvasculature. The microspheres are loaded with the radioactive yttrium-90, a high-energy beta-emitting isotope with a half-life of 64.1 hours. SIR-Spheres microspheres are manufactured by Sirtex Medical.
- Behavioral: QLQ-C30 with HCC module
In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT will incorporate a quality-of-life questionnaire. CIRT will be using EORTC's QLQ-C30 with HCC Module to measure changes in the quality of life of the patient. The quality-of-life questionnaire will be offered to the patient before the treatment, shortly after the treatment (as soon as possible) and at every follow-up. Filling out the quality-of-life questionnaire is entirely voluntary for the patient
- Description of the clinical context in which SIR-Spheres are applied [ Time Frame: Baseline, follow-up every 3 months until 24 months ]Context of systemic therapy; intention of treatment; prior hepatic procedures; post hepatic procedures
- Overall Survival (OS) [ Time Frame: min 24 months ]Survival in months from time of SIR-Spheres treatment
- Incidence of Treatment-Emergent Adverse Events (Safety) [ Time Frame: min 24 months ]Incidence of Treatment-Emergent Adverse Events
- QLQ-C30 [ Time Frame: Every 3 months until 24 months ]Quality of life using QLQ-C30 from baseline until 24 months
- Progression free survival (PFS) [ Time Frame: min 24 months ]Progression free survival in months from time of treatment
- Liver specific progression free survival [ Time Frame: min 24 months ]Progression free survival in the liver in months from time of treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03256994
|Contact: Agnes Walk||+43 1 904 2003 firstname.lastname@example.org|
|Contact: Niels de Jong||+43 1 904 2003 email@example.com|
|Contact: Antoine Bouvier, Dr|
|Contact: Maxime Ronot, Dr|
|Chu de Dijon||Recruiting|
|Contact: Romaric Loffroy, Dr|
|Centre Léon Bérard||Recruiting|
|Contact: Charles Mastier, Dr|
|CHRU de Strasbourg||Recruiting|
|Contact: Michel Greget, Dr|
|Study Chair:||José I Bilbao, Prof||Cardiovascular and Interventional Radiological Society of Europe|